Cargando…

The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model

BACKGROUND: Chronic kidney disease (CKD) is a worldwide health problem that its incidence increases nowadays with the increase in the risk of environmental pollution. CKD can progress to end-stage renal disease (ESRD) which usually ends fatally. This study aimed to examine the therapeutic potential...

Descripción completa

Detalles Bibliográficos
Autores principales: El Miniawy, Hala M. F., Farghali, Haithem A., Khattab, Marwa S., Emam, Ibrahim A., Ibrahem, Essam M., Sabry, Dina, Ismail, Tahany A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338563/
https://www.ncbi.nlm.nih.gov/pubmed/35908006
http://dx.doi.org/10.1186/s13287-022-03076-8
_version_ 1784759996972531712
author El Miniawy, Hala M. F.
Farghali, Haithem A.
Khattab, Marwa S.
Emam, Ibrahim A.
Ibrahem, Essam M.
Sabry, Dina
Ismail, Tahany A.
author_facet El Miniawy, Hala M. F.
Farghali, Haithem A.
Khattab, Marwa S.
Emam, Ibrahim A.
Ibrahem, Essam M.
Sabry, Dina
Ismail, Tahany A.
author_sort El Miniawy, Hala M. F.
collection PubMed
description BACKGROUND: Chronic kidney disease (CKD) is a worldwide health problem that its incidence increases nowadays with the increase in the risk of environmental pollution. CKD can progress to end-stage renal disease (ESRD) which usually ends fatally. This study aimed to examine the therapeutic potential of Camel Wharton jelly-mesenchymal stem cells (CWJ-MSCs) in chronic kidney disease model induced in dogs. METHODS: CWJ-MSCs were injected directed to the kidney with ultrasonographic guidance in dogs with 5/6 nephrectomy to evaluate its therapeutic potency in such cases. Analysis of variance was applied in normally distributed quantitative variables while a non-parametric Mann–Whitney test was used for non-normally distributed quantitative variables. RESULTS: The serum urea and creatinine in the treated group were significantly decreased transferring dogs in the treated group from stage 3 to stage 2 CKD according to the IRIS staging system. Histopathology of renal tissue revealed improving CKD lesions by increasing regeneration of degenerated tubules, maintaining the integrity of glomeruli. New vascularization with blood vessels remodeling were common findings. Periodic acid Schiff stain of renal tissue showed the integrity of renal tubules and thickness of the glomerular basement membrane. Fibrosis of cortex and medulla was lower in the treated group than in the CKD model as monitored by Mallory’s trichrome stain (MTC). NGAL and KIM-1 genes expression were decreased while VEGF and EGF genes expression were increased indicating renal tissue repair. CONCLUSIONS: CWJ-MSCs have a therapeutic potential in the CKD model induced in dogs.
format Online
Article
Text
id pubmed-9338563
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93385632022-07-31 The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model El Miniawy, Hala M. F. Farghali, Haithem A. Khattab, Marwa S. Emam, Ibrahim A. Ibrahem, Essam M. Sabry, Dina Ismail, Tahany A. Stem Cell Res Ther Research BACKGROUND: Chronic kidney disease (CKD) is a worldwide health problem that its incidence increases nowadays with the increase in the risk of environmental pollution. CKD can progress to end-stage renal disease (ESRD) which usually ends fatally. This study aimed to examine the therapeutic potential of Camel Wharton jelly-mesenchymal stem cells (CWJ-MSCs) in chronic kidney disease model induced in dogs. METHODS: CWJ-MSCs were injected directed to the kidney with ultrasonographic guidance in dogs with 5/6 nephrectomy to evaluate its therapeutic potency in such cases. Analysis of variance was applied in normally distributed quantitative variables while a non-parametric Mann–Whitney test was used for non-normally distributed quantitative variables. RESULTS: The serum urea and creatinine in the treated group were significantly decreased transferring dogs in the treated group from stage 3 to stage 2 CKD according to the IRIS staging system. Histopathology of renal tissue revealed improving CKD lesions by increasing regeneration of degenerated tubules, maintaining the integrity of glomeruli. New vascularization with blood vessels remodeling were common findings. Periodic acid Schiff stain of renal tissue showed the integrity of renal tubules and thickness of the glomerular basement membrane. Fibrosis of cortex and medulla was lower in the treated group than in the CKD model as monitored by Mallory’s trichrome stain (MTC). NGAL and KIM-1 genes expression were decreased while VEGF and EGF genes expression were increased indicating renal tissue repair. CONCLUSIONS: CWJ-MSCs have a therapeutic potential in the CKD model induced in dogs. BioMed Central 2022-07-30 /pmc/articles/PMC9338563/ /pubmed/35908006 http://dx.doi.org/10.1186/s13287-022-03076-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
El Miniawy, Hala M. F.
Farghali, Haithem A.
Khattab, Marwa S.
Emam, Ibrahim A.
Ibrahem, Essam M.
Sabry, Dina
Ismail, Tahany A.
The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
title The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
title_full The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
title_fullStr The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
title_full_unstemmed The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
title_short The therapeutic potential of Camel Wharton jelly mesenchymal stem cells (CWJ-MSCs) in canine chronic kidney disease model
title_sort therapeutic potential of camel wharton jelly mesenchymal stem cells (cwj-mscs) in canine chronic kidney disease model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338563/
https://www.ncbi.nlm.nih.gov/pubmed/35908006
http://dx.doi.org/10.1186/s13287-022-03076-8
work_keys_str_mv AT elminiawyhalamf thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT farghalihaithema thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT khattabmarwas thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT emamibrahima thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT ibrahemessamm thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT sabrydina thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT ismailtahanya thetherapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT elminiawyhalamf therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT farghalihaithema therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT khattabmarwas therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT emamibrahima therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT ibrahemessamm therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT sabrydina therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel
AT ismailtahanya therapeuticpotentialofcamelwhartonjellymesenchymalstemcellscwjmscsincaninechronickidneydiseasemodel